Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02998541 · ClinicalTrials.gov registry record · Phase 3
Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo
A Phase 3 study, sponsored by Shire.
- Terminated
- Registry status
- Phase 3
- Development phase
- 219
- Enrollment target
NCT02998541 is a Phase 3 study that was terminated before completion, run by Shire. The registered enrollment target is 219 participants.
The verdict
NCT02998541, a Phase 3 study, was terminated before completion, sponsored by Shire.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 219 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if an investigational treatment is effective compared with placebo and PVP-Iodine in the treatment of adults and children with adenoviral conjunctivitis.
Interventions
- OTHER Placebo
- DRUG SHP640
- DRUG PVP-I 0.6%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2017-03-27 |
| Est. Completion | 2019-05-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02998541
The ClinicalTrials.gov registry entry for NCT02998541 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02998541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02998541 about?
NCT02998541 is a clinical study titled "Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo". The purpose of this study is to determine if an investigational treatment is effective compared with placebo and PVP-Iodine in the treatment of adults and children with adenoviral conjunctivitis.
What is the current status of trial NCT02998541?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 219 participants. The study started on 2017-03-27. Estimated completion is 2019-05-13.
What interventions are being tested in trial NCT02998541?
The interventions under investigation include: Placebo (OTHER), SHP640 (DRUG), PVP-I 0.6% (DRUG).
Who is sponsoring clinical trial NCT02998541?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.